Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.
Summary
Improved survival rates for reproductive-age breast cancer patients highlight significant oncofertility challenges. Fertility preservation, gonadotoxicity, and pregnancy safety are key concerns requiring early and integrated management within the therapeutic plan. Prompt referral for fertility preservation is crucial, ensuring it does not compromise oncologic outcomes. Modern therapies such as PARP inhibitors, CDK4/6 inhibitors, HER2-monoclonal antibodies, and endocrine treatments raise specific questions due to a lack of prospective human fertility data. A precautionary approach is recommended, including effective contraception and adherence to washout periods.
Analysis
This article is crucial as it highlights critical knowledge gaps regarding the impact of modern anti-cancer therapies on fertility in breast cancer patients. It underscores the importance of a multidisciplinary oncofertility approach, integrating counseling from diagnosis and planning for fertility preservation. For clinical practice, it emphasizes the need for transparent communication with patients about uncertainties and the adoption of preventive measures. In terms of translational research, it calls for the integration of standardized reproductive endpoints into clinical trials and the development of predictive tools to optimize long-term survivorship care.